Navigation Links
Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Date:12/8/2008

SEATTLE, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that extended follow-up data for the Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent (FIT) study presented at the American Society of Hematology (ASH) 50th Annual Meeting by Morschhauser, et al demonstrated the continued improvement in progression-free survival (PFS) following Zevalin consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieved a response to first line therapy over chemotherapy alone. Additionally, Zevalin consolidation did not adversely affect the use of various effective second-line treatments including stem cell transplants in patients who relapsed.

"The FIT study follow-on results are quite impressive when one considers that the median progression free survival for the Zevalin recipients that achieved a complete remission (CR) after induction therapy has not yet been reached with an estimated 67 months compared to 30 months with chemotherapy alone," said James A. Bianco, M.D., CEO of Cell Therapeutics. "A single dose of consolidation that could allow patients with a CR from requiring additional treatment for their NHL for over 3 years represents a significant advancement in the treatment of this disease."

The multinational, randomized phase III FIT study evaluated the benefit and safety of a single infusion of Zevalin in patients with follicular B-cell non-Hodgkin's lymphoma who had achieved a partial remission (PR) or a complete remission / complete remission unconfirmed (CR/CRu) after receiving standard first-line chemotherapy regimens. Patients were randomized to either Zevalin consolidation or no further therapy. The FIT trial results were first presented at the December 2007 ASH annual meeting. The results were subsequently published in Journal of Clinical Oncology 2008 26(32):5156-64. At the 2008 ASH meeting, the investigators prese
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
2. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
3. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
4. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 NxStage Medical, ... of innovative dialysis products, announced today that the ... its System One™ to perform hemodialysis overnight while ... home nocturnal hemodialysis. NxStage,s® System One is the ... FDA for this indication. Home ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "Investment Analysis of the ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the US medical device sector identifies the key ... venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
(Date:12/26/2014)... Cooking and warming equipment ... 5. This score reflects slightly positive negotiation conditions for ... low switching costs and a low level of price ... availability of substitutes for cooking and warming equipment and ... aluminum, key inputs in the production process of this ...
(Date:12/26/2014)... FL (PRWEB) December 26, 2014 India ... health insurance in the USA, announced today a new ... assist members in choosing the right plan for their ... the complexity out of the selection process when choosing ... by age group with only a few clicks. Many ...
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... December 25, 2014 BambooFlooringChina.com sells many ... quality bamboo flooring. Today, the company announces big ... many styles and colors. , BambooFlooringChina.com is the world’s ... the promotion is valid until Jan. 20, 2015. , ... and woven with a natural thread. All the bamboo ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... ... ... they now offer pet insurance to the state of Hawaii. Beginning immediately, residents of ... and cat owners of Hawaii have more options when it comes to pet insurance. , , ...
... ... leader in biofeedback and Mediwatch plc team up to offer a range of pelvic ... ... diagnostic manufacturing company, and Thought Technology Ltd., the worldwide leading expert in biofeedback, have ...
... ... a nightmare for pets and their owners, without a safety system in place.,Pets Guardian ... an accident or other unforeseen event., , ... (PRWEB) July 2, 2010 -- With vacation time here and ...
... First ... multi -million dollar contract for Exclusive Distributorship rights this week with the U.A.E Embassy ... new revolutionary product First Defense Nasal Screens to the entire Arab World. , ... Washington D. C. (PRWEB) -- First ...
... A time of ... according to Washington, D.C., personal injury attorney Mike Abelson. , ... Washington, D.C. (PRWEB) July 4, 2010 -- There is no ... Abelson says. But on the holiday day designated to celebrate the freedoms we all ...
... Neuxpower, A ... 2010 Emerging Technology Vendor By CRN Magazine. , ... Philadelphia, PA (PRWEB) July 4, 2010 -- Neuxpower ( www.neuxpower.com ), a ... 2010 Emerging Technology Vendor by CRN Magazine. Neuxpower was one of a select group of ...
Cached Medicine News:Health News:Pet Insurance from Trupanion Becomes Available in Hawaii 2Health News:OEM Partnership Between Thought Technology Ltd. and Mediwatch plc 2Health News:OEM Partnership Between Thought Technology Ltd. and Mediwatch plc 3Health News:Pets Guardian Provides A Pet Safety System, Ensuring Pets Will Be Cared For In Case of a Personal Emergency 2Health News:Pets Guardian Provides A Pet Safety System, Ensuring Pets Will Be Cared For In Case of a Personal Emergency 3Health News:United Staes Company, First Defense Nasal Screens Signs Multi-Million Dollar Exclusive Distributorship Contract with U.A.E Company. 2Health News:Don't Drink and Drive on Fourth of July Weekend, Washington, D.C., Attorney Warns 2Health News:Neuxpower Selected as 2010 Emerging Technology Vendor by CRN Magazine 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: